Sign In
Buy KURA
$8.66
-0.315 (-3.51%)
At Close: Jun 03, 2026
Kura Oncology Announces Senior Executive Promotions
04:30pm, Monday, 06'th Jan 2025
– Mollie Leoni, M.D. promoted to Chief Medical Officer – – Francis Burrows, Ph.D.
Kura Oncology Presents Deep Value At Today's Prices (Rating Upgrade)
01:46pm, Wednesday, 18'th Dec 2024
Kura Oncology, Inc.'s collaboration with Kyowa Kirin brings $330M upfront and a potential $1.2B in milestone payments, enhancing long-term shareholder value despite initial market disappointment. Zift
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
07:00am, Monday, 09'th Dec 2024
– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 –
Kura Oncology to Host Virtual Investor Event on December 9, 2024
07:30am, Monday, 02'nd Dec 2024
Live webcast and conference call to discuss presentation of updated data from KOMET-007 combination trial of ziftomenib at ASH Live webcast and conference call to discuss presentation of updated data
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
07:30am, Monday, 25'th Nov 2024
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
05:52pm, Wednesday, 20'th Nov 2024
Kura Oncology said on Wednesday it will collaborate with Japan's Kyowa Kirin to develop and commercialize the blood cancer therapy ziftomenib.
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
05:00pm, Wednesday, 20'th Nov 2024
– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – �
Kura Oncology, Inc. (KURA) Q3 2024 Earnings Call Transcript
05:54am, Saturday, 09'th Nov 2024
Kura Oncology, Inc. (NASDAQ:KURA ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Do
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
09:09am, Tuesday, 05'th Nov 2024
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r adverse risk AML patients selected for oral presentation on Saturday, December 7th –
Kura Oncology to Report Third Quarter 2024 Financial Results
07:30am, Thursday, 31'st Oct 2024
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
07:30am, Thursday, 24'th Oct 2024
– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models –
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors
07:30am, Wednesday, 23'rd Oct 2024
– New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics – – New preclinical data to be presented at EORTC-NCI-AACR Symposium on Molecular
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology
06:30pm, Monday, 30'th Sep 2024
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors
07:30am, Tuesday, 17'th Sep 2024
SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment
Kura Oncology, Inc. (KURA) Q2 2024 Earnings Call Transcript
02:07pm, Friday, 09'th Aug 2024
Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Pete De Spain - Head, IR Troy Wilson - President and CEO Thomas Doyle - SVP of Financ
